Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, according to a new study led by UCL researchers.
When genetic testing reveals a rare DNA mutation, doctors and patients are frequently left in the dark about what it actually means. Now, researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful new way to determine whether a patient with a mutation is likely to actually develop disease, a concept known in genetics as penetrance.
Current ALS diagnosis relies on neurological evaluations and the presence of symptoms; at present, there is no definitive diagnostic test.
A first-of-its-kind Blood Pressure Treatment Efficacy Calculator built on data from nearly 500 randomized clinical trials in over 100,000 people allows doctors to see how much different medications are likely to lower blood pressure.
A novel, multi-analyte test developed by researchers at the Johns Hopkins Kimmel Cancer Center, its Ludwig Center and the Johns Hopkins Department of Neurosurgery can accurately identify brain cancers using small samples of cerebrospinal fluid (CSF), offering a promising new tool to guide clinical decision-making.
Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia, according to two studies published in Blood Advances.
Scientists at Kumamoto University have made a major breakthrough in regenerative medicine by successfully creating functional ureter tissue—organoids resembling the urinary tract—from pluripotent stem cells.
The eye, like most organs, has an intricate plumbing system. Pressure builds when drainage is impaired, and this condition—glaucoma—can cause irreversible vision loss. Certain popular anti-inflammatory eye medications that contain steroids can in some cases compound the problem, although scientists have been at a loss to understand why.
PocDoc, a leading UK digital health diagnostics company, has launched what it says is the world’s first smartphone-based test for type 2 diabetes risk including the gold-standard blood biomarker, HbA1c, a landmark step in diabetes prevention according to the company.
An AI tool could help cardiologists identify and target cells that trigger arrhythmia in patients with ventricular tachycardia, a serious heart condition.